Pre-made Alirocumab biosimilar ( Whole mAb, anti-PCSK9 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-016
Anti-PCSK9 therapeutic antibody (Pre-made Alirocumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PCSK9 therapeutic antibody (Pre-made Alirocumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital|
|Conditions Approved||Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias|
|Conditions Active||Coronary artery disease|
|Development Tech||VelocImmune Mouse|